Skip to main content
Journal cover image

Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Publication ,  Journal Article
Franklin, ME; Sapyta, J; Freeman, JB; Khanna, M; Compton, S; Almirall, D; Moore, P; Choate-Summers, M; Garcia, A; Edson, AL; Foa, EB; March, JS
Published in: JAMA
September 21, 2011

CONTEXT: The extant literature on the treatment of pediatric obsessive-compulsive disorder (OCD) indicates that partial response to serotonin reuptake inhibitors (SRIs) is the norm and that augmentation with short-term OCD-specific cognitive behavior therapy (CBT) may provide additional benefit. OBJECTIVE: To examine the effects of augmenting SRIs with CBT or a brief form of CBT, instructions in CBT delivered in the context of medication management. DESIGN, SETTING, AND PARTICIPANTS: A 12-week randomized controlled trial conducted at 3 academic medical centers between 2004 and 2009, involving 124 pediatric outpatients between the ages of 7 and 17 years with OCD as a primary diagnosis and a Children's Yale-Brown Obsessive Compulsive Scale score of 16 or higher despite an adequate SRI trial. INTERVENTIONS: Participants were randomly assigned to 1 of 3 treatment strategies that included 7 sessions over 12 weeks: 42 in the medication management only, 42 in the medication management plus instructions in CBT, and 42 in the medication management plus CBT; the last included 14 concurrent CBT sessions. MAIN OUTCOME MEASURES: Whether patients responded positively to treatment by improving their baseline obsessive-compulsive scale score by 30% or more and demonstrating a change in their continuous scores over 12 weeks. RESULTS: The medication management plus CBT strategy was superior to the other 2 strategies on all outcome measures. In the primary intention-to-treat analysis, 68.6% (95% CI, 53.9%-83.3%) in the plus CBT group were considered responders, which was significantly better than the 34.0% (95% CI, 18.0%-50.0%) in the plus instructions in CBT group, and 30.0% (95% CI, 14.9%-45.1%) in the medication management only group. The results were similar in pairwise comparisons with the plus CBT strategy being superior to the other 2 strategies (P < .01 for both). The plus instructions in CBT strategy was not statistically superior to medication management only (P = .72). The number needed-to-treat analysis with the plus CBT vs medication management only in order to see 1 additional patient at week 12, on average, was estimated as 3; for the plus CBT vs the plus instructions in CBT strategy, the number needed to treat was also estimated as 3; for the plus instructions in CBT vs medication management only the number needed to treat was estimated as 25. CONCLUSIONS: Among patients aged 7 to 17 years with OCD and partial response to SRI use, the addition of CBT to medication management compared with medication management alone resulted in a significantly greater response rate, whereas augmentation of medication management with the addition of instructions in CBT did not. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00074815.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

September 21, 2011

Volume

306

Issue

11

Start / End Page

1224 / 1232

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Selective Serotonin Reuptake Inhibitors
  • Obsessive-Compulsive Disorder
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Combined Modality Therapy
  • Cognitive Behavioral Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Franklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D., … March, J. S. (2011). Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA, 306(11), 1224–1232. https://doi.org/10.1001/jama.2011.1344
Franklin, Martin E., Jeffrey Sapyta, Jennifer B. Freeman, Muniya Khanna, Scott Compton, Daniel Almirall, Phoebe Moore, et al. “Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.JAMA 306, no. 11 (September 21, 2011): 1224–32. https://doi.org/10.1001/jama.2011.1344.
Franklin, Martin E., et al. “Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.JAMA, vol. 306, no. 11, Sept. 2011, pp. 1224–32. Pubmed, doi:10.1001/jama.2011.1344.
Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, Foa EB, March JS. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011 Sep 21;306(11):1224–1232.
Journal cover image

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

September 21, 2011

Volume

306

Issue

11

Start / End Page

1224 / 1232

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Selective Serotonin Reuptake Inhibitors
  • Obsessive-Compulsive Disorder
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Combined Modality Therapy
  • Cognitive Behavioral Therapy